Utility of a Liquid Formulation of Levo-thyroxine in Differentiated Thyroid Cancer Patients

Abstract

The goal of levo-thyroxine (L-T4) administration in differentiated thyroid cancer (DTC) is to suppress thyroid stimulating hormone (TSH) levels. The tolerability and efficacy of a new formulation of liquid L-T4 vs. the previous tablet formulation was evaluated in a cohort of 59 patients with cured DTC. The correlation between breakfast modality and therapy was also monitored. Hormonal and clinical evaluations were performed before and 70 days after patients were switched from tablet to liquid L-T4 formulation, without changes in daily dose. Breakfast habits were evaluated. The interval between L-T4 therapy and breakfast was recorded. Patient approval of L-T4 formulations was evaluated. 8% of patients dropped out owing to adverse events. The modality of L-T4 administration proved adequate under tablet and liquid formulation in 64% and 68% of patients who fully complied with the protocol. While significantly more patients found the tablet formulation more agreeable, at the end of the protocol subjective symptoms had diminished significantly and 73% requested to remain on the liquid formulation. No change in TSH, thyroid hormones or thyroglobulin was noted during the study. A balanced breakfast containing less than 4 g of alimentary fibre did not interfere with L-T4 therapy. Liquid L-T4 seems to be a valid alternative formulation in DTC patients, its initial dislike being outweighed by a significant reduction in subjective symptoms. Both tablet and liquid L-T4 therapy require monitoring over time. A continental breakfast containing less than 4 g of alimentary fibres seems to favour the absorption of L-T4, whether in tablet or liquid formulation.

Key words

liquid L-T4 - differentiated thyroid cancer - continental breakfast

• References

• 1 Li N, Du XL, Reitzel LR et al. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008. Thyroid 2013; 23: 103-110
• 2 Van den Bruel A, Francart J, Dubois C et al. Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management. J Clin Endocrinol Metab 2013; 98: 4063-4071
• 3 Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: The Role of endocrinologists and ultrasounds. Thyroid 2013; 24: 472-479
• 4 Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 2008; 37: 419-435
• 5 Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20: 135-146
• 6 Giusti M, Melle G, Fenocchio M et al. Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. J Zhejiang Univ Sci B 2011; 12: 163-173
• 7 Canaris GJ, Manowitz NR, Mayor G et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526-534
• 8 Batrinos ML. The problem of exogenous subclinical hyperthyroidism. Hormones (Athens) 2006; 5: 119-125
• 9 Delemer B, Aubert JP, Nys P et al. An observational study of the initial management of hypothyroidism in France: the ORCHIDÉE study. Eur J Endocrinol 2012; 167: 817-823
• 10 Lam E, Strugnell SS, Bajdik C et al. Limited adequacy of thyroid cancer patient follow-up at a Canadian tertiary care centre. Can J Surg 2013; 56: 385-392
• 11 Hasselström K, Siersbæk-Nielsen K, Lumholtz IB et al. The bioavailability of thyroxine and 3,5,3′-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. Acta Endocrinol (Copenh) 1985; 110: 483-486
• 12 Liwampo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab 2009; 23: 781-792
• 13 Gkotsina M, Michalaki M, Mamali I et al. Improved levothyroxine pharmacokinetics after bariatric surgery. Thyroid 2013; 23: 414-419
• 14 Read DG, Hays MT, Hershman JM. Absorption of oral thyroxine in hypothyroid and normal man. J Clin Endocrinol Metab 1970; 30: 798-799
• 15 Barbesino G. Drugs affecting thyroid function. Thyroid 2010; 20: 763-770
• 16 Colucci P, Yue CS, Ducharme M et al. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol 2013; 9: 40-47
• 17 Klop B., Elte JWF, Cabezas MC. Dyslipidemia in obesity: Mechanism and potential targets. Nutrients 2013; 5: 1218-1240
• 18 Rizos CV, Elisaf MS. Metformin and cancer. Eur J Pharmacol 2013; 705: 96-108
• 19 Pazaitou-Panayiotou K, Polyzos SA, Mantzoros CS. Obesity and thyroid cancer: epidemiologic associations and underlying mechanisms. Obes Rev 2013; 14: 1006-1022
• 20 Giusti M, Mortara L, Degrandi R et al. Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study. Thyroid Res 2008; 1
• 21 Kuijpens JL, Janssen-Heijnen ML, Lemmens VE et al. Comorbidity in newly diagnosed thyroid cancer patients: a population-based study on prevalence and the impact on treatment and survival. Clin Endocrinol 2006; 64: 450-455
• 22 Santini F, Pinchera A, Marsili A et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 2005; 90: 124-127
• 23 Lamson MJ, Pamplin CL, Rolleri RI et al. Quantitation of a substantial reduction in levothyroxine (T4) adsorption by food. Thyroid 2004; 14: 876
• 24 Bach-Hunh TG, Bach-Huynh TG, Nayak B et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab 2009; 94: 3905-3912
• 25 Vita R, Saraceno G, Trimarchi F et al. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 2013; 43: 154-160
• 26 Klein I. Clinical, metabolic, and organ-specific indices of thyroid function. Endocrinol Metab Clin North Am 2001; 30: 415-427
• 27 Cappelli C, Pirola I, Formanti A et al. Oral liquid levothyroxine treatment at breakfast: a mistake?. Eur J Endocrinol 2014; 170: 95-99
• 28 Benvenga S, Bartolone L, Pappalardo MA et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 2008; 18: 293-301
• 29 Lilja JI, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol 2005; 60: 337-341
• 30 Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab 1996; 81: 857-859
• 31 Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 1998; 8: 667-671
• 32 Zeitler P, Solberg P. Pharmacy & Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Food and levothyroxine administration in infants and children. J Pediatr 2010; 157: 13-14
• 33 Klein I, Danzi S. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease. Thyroid 2003; 13: 1127-1132
• 34 Hennessey JV. Generic vs name brand L-thyroxine products: interchangeable or still not?. J Clin Endocrinol Metab 2013; 98: 511-514
• 35 Carpi A, Toscano S. Clinical use of a new pharmaceutical preparation containing L-thyroxine in solution. Preliminary report. Thyroidology 1989; 1: 45-48
• 36 Carpi A, Toni MG, Maccheroni M et al. Long term therapy with a new liquid L-thyroxine preparation: bioequivalence with L-T4 tablets. Thyroidology 1992; 4: 115-119
• 37 Yannovits N, Zintzaras E, Pouli A et al. A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers. Eur J Drug Metab Pharmacokinet 2006; 31: 73-78
• 38 Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 2012; 62: 631-636
• 39 Brancato D, Scorsone S, Saura G et al. Comparison of TSH levels with liquid formulation versus tablet formulation of levothyroxine in the treatment of adult hypothyroidism. Endocr Practice 2013;